NCM
AURA icon

Nantahala Capital Management’s Aura Biosciences AURA Stock Holding History

Nantahala Capital Management’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Buy
2,951,030
+833,333
+39% +$5.96M 0.69% 40
2026
Q1 		$14.2M Hold
2,117,697
– – 0.52% 52
2025
Q4 		$11.5M Hold
2,117,697
– – 0.38% 61
2025
Q3 		$13.1M Hold
2,117,697
– – 0.45% 51
2025
Q2 		$13.3M Buy
2,117,697
+850,000
+67% +$4.97M 0.52% 43
2025
Q1 		$7.43M Sell
1,267,697
-2,338
-0.2% -$17.7K 0.3% 53
2024
Q4 		$10.4M Hold
1,270,035
– – 0.45% 45
2024
Q3 		$11.3M Hold
1,270,035
– – 0.57% 35
2024
Q2 		$9.6M Sell
1,270,035
-51,825
-4% -$380K 0.56% 35
2024
Q1 		$10.4M Hold
1,321,860
– – 0.59% 34
2023
Q4 		$11.7M Buy
1,321,860
+577,968
+78% +$4.89M 0.7% 28
2023
Q3 		$6.67M Sell
743,892
-59,433
-7% -$639K 0.57% 41
2023
Q2 		$9.92M Sell
803,325
-40,121
-5% -$429K 0.96% 26
2023
Q1 		$7.83M Buy
843,446
+44,695
+6% +$464K 0.6% 38
2022
Q4 		$8.39M Buy
798,751
+414,987
+108% +$5.28M 0.54% 39
2022
Q3 		$6.95M Buy
383,764
+40,549
+12% +$614K 0.45% 49
2022
Q2 		$4.86M Buy
343,215
+41,225
+14% +$682K 0.24% 63
2022
Q1 		$6.64M Buy
301,990
+202,844
+205% +$3.86M 0.29% 58
2021
Q4 		$1.68M Buy
+99,146
New +$1.77M 0.06% 111

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Nantahala Capital Management's AURA Position: Q2 2026 in Review

Nantahala Capital Management increased its Aura Biosciences (AURA) stake by 39% in Q2 2026, buying an estimated $5.96M and bringing the position to 2,951,030 shares worth $21M. The position accounts for 0.69% of the portfolio, ranked #40.

Nantahala Capital Management first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Nantahala Capital Management held 2,951,030 shares of Aura Biosciences worth $21M as of Q2 2026.
  • Nantahala Capital Management bought 833,333 Aura Biosciences shares in Q2 2026, an estimated $5.96M.
  • Aura Biosciences made up 0.69% of Nantahala Capital Management's portfolio in Q2 2026, its #40 holding.
  • Nantahala Capital Management first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.